Cargando…
NECTIN4: A Novel Therapeutic Target for Melanoma
Malignant melanoma is the most common lethal skin cancer and causes death in a short time when metastasized. Although BRAF inhibitors (BRAFi) have greatly improved the prognosis of BRAF-mutated melanoma, drug resistance is a major concern even when they are combined with MEK inhibitors. Alternative...
Autores principales: | Tanaka, Yuka, Murata, Maho, Shen, Che-Hung, Furue, Masutaka, Ito, Takamichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835875/ https://www.ncbi.nlm.nih.gov/pubmed/33478111 http://dx.doi.org/10.3390/ijms22020976 |
Ejemplares similares
-
Nectin Cell Adhesion Molecule 4 (NECTIN4) Expression in Cutaneous Squamous Cell Carcinoma: A New Therapeutic Target?
por: Tanaka, Yuka, et al.
Publicado: (2021) -
NECTIN4 Expression in Extramammary Paget’s Disease: Implication of a New Therapeutic Target
por: Murata, Maho, et al.
Publicado: (2020) -
Nectin cell adhesion molecule 4 regulates angiogenesis through Src signaling and serves as a novel therapeutic target in angiosarcoma
por: Tanaka, Yuka, et al.
Publicado: (2022) -
Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020) -
OVOL2-Mediated ZEB1 Downregulation May Prevent Promotion of Actinic Keratosis to Cutaneous Squamous Cell Carcinoma
por: Murata, Maho, et al.
Publicado: (2020)